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 Abstract 
Extrapolations of parametric survival models fitted to censored data are routinely used in the 
assessment of health technologies to estimate mean survival, particularly in diseases that potentially 
reduce the life expectancy of patients. 
Akaike’s Information Criterion (AIC) and Bayesian Information Criterion (BIC) are commonly used in 
health technology assessment alongside an assessment of plausibility to determine which statistical 
model best fits the data and should be used for prediction of long term treatment effects. We 
compare fit and estimates of restricted mean survival time (RMST) from eight parametric models, 
and contrast models preferred in terms of AIC, BIC and log-likelihood, without considering model 
plausibility. We assess the methods’ suitability for selecting a parametric model through simulation 
of data replicating the follow-up of intervention arms for various time-to-event outcomes from four 
clinical trials. Follow-up was replicated through the consideration of recruitment duration, minimum 
and maximum follow-up times. 10,000 simulations of each scenario were performed. 
We demonstrate that the different methods can result in disagreement over the best model, and 
that it is inappropriate to base model selection solely on goodness-of-fit statistics without 
consideration of hazard behaviour and plausibility of extrapolations. We show that typical trial 
follow-up can be unsuitable for extrapolation, resulting in unreliable estimation of multiple 
parameter models, and infer that selecting survival models based only on goodness-of-fit statistics is 
unsuitable due to the high level of uncertainty in a cost-effectiveness analysis. 
This paper demonstrates the potential problems of over-reliance on goodness-of-fit statistics when 
selecting a model for extrapolation. When follow-up is more mature, BIC appears superior to the 
other selection methods, selecting models with the most accurate and least biased estimates of 
RMST. 
  
1 Introduction 
1.1 Background 
In England and Wales, when a medical device or pharmacological developer wishes to get a 
technology approved for a new indication, they submit a report containing clinical and cost 
effectiveness evidence concluding that their technology will offer cost-effective benefit to the 
National Health Service (NHS). Usually a submission will include an economic model, which captures 
the benefit of the intervention across a patient’s lifetime through the estimation of the mean 
survival time. Depending on the indication, this model may be required to extrapolate beyond the 
observed data to predict the future performance of the intervention and its comparators, as the 
data will often be heavily censored due to limited trial follow-up. The optimal extrapolation from 
data for time-to-event outcomes, such as overall survival, is routinely a point of contention within 
the decision-making process, and is often influential on the conclusion of the appraisal.  
The National Institute of Health and Care Excellence (NICE) are responsible for deciding which 
treatments should be reimbursed by the NHS. Many have their clinical and cost-effectiveness 
assessed through the single technology appraisal (STA) process, where evidence submitted by a 
pharmaceutical company is appraised by an independent evidence review group prior to a 
discussion and decision by a NICE technology appraisal committee. The committee will consider 
whether the treatment is both clinically and cost-effective, with the latter assessed through 
incremental cost-effectiveness ratio (ICER), which divides the incremental benefit of the new 
therapy by the incremental cost. The ICER can vary considerably based on the time-to-event 
extrapolation. If the most plausible ICER falls below certain thresholds, the treatment would usually 
be considered cost-effective and be recommended for reimbursement. 
A recent review [1] reported that the time horizons of economic models included in submissions to 
the NICE for cancer interventions in 2017 was on average 31.4 years (range 10 years to 100 years) 
and fifteen times the median follow-up period,  demonstrating the importance of reliable and robust 
methods for extrapolation. 
1.2 Methods for model selection 
The most common approach to extrapolation in NICE appraisals is to select a single model from a 
range of parametric models (e.g. exponential) [1, 2]. Candidate models are usually compared on two 
metrics: on the goodness-of-fit to the observed data, and on the plausibility of the extrapolations. 
This paper considers the former, since the plausibility of extrapolations can only objectively be 
demonstrated when suitably mature data are available. Plausibility would usually be assessed 
through a comparison of predictions of the percentage of patients who remain event-free following 
a certain length of follow-up. Ideally these assessment of plausibility are made comparing to 
relevant studies with longer observed follow-up, but if this is unavailable then it is necessary rely on 
the opinions of clinical experts. Whilst expert opinion from clinicians and experienced analysts may 
offer valuable insight into the plausibility of certain models and their extrapolations compared to 
known patterns of disease, these opinions may not always agree especially when considering novel 
therapies.  
Goodness-of-fit is often assessed visually, e.g. comparing models to Kaplan-Meier curves or 
cumulative hazard plots. Whilst assessing visual fit may sometimes rule out particular models, it can 
be difficult to distinguish between most models due to their similar appearance, justifying a need for 
a less subjective approach. Hence, there is increased reliance on statistical comparisons to assess the 
goodness-of-fit.  
A well-established measure of model fit is the -2·log-likelihood statistic, where a lower score 
suggests a better fit. The statistic can compare two nested models in a formal hypothesis test, the 
likelihood ratio test. In this paper, we compare both nested and non-nested models and so can only 
perform a simple comparison of the log-likelihood statistics. Figure 1 visualises the nesting 
relationships for the models that we consider in this paper. When comparing models with a large 
number of potential covariates, relying solely on the log-likelihood can result in the selection of an 
overfitted model. Although survival extrapolation models often exclude covariates, they may have 
different numbers of parameters due to the different parameterisations of the survival models.  
Models with more parameters may be at greater risk of overfitting. 
Akaike’s information criterion (AIC) expands on the log-likelihood. AIC includes a penalty based on 
the number of parameters in the model, with the aim of selecting a parsimonious model, rather than 
the best fitting model. When presenting his information criterion, Akaike demonstrated that relying 
on the maximised log-likelihood alone could bias the model selection, but that this bias was 
approximately equal to the number of estimable parameters under certain conditions [3]. The AIC is 
therefore defined as  
(1) 
where L is the likelihood and K the number of parameters in the model, meaning that the model 
with the lowest AIC is the closest of the candidate models to the true model. 
The Bayesian information criterion (BIC), derived by Schwarz [4], uses a different weighting for the 
number of parameters, multiplying the penalty of the AIC by the natural logarithm of, n,  to give  
    (2) 
where n is either more commonly the number of observations, as in this paper, or the number of 
events as recommended by Volinksy and Raftery [5]. Whilst the log-likelihood, AIC and BIC can often 
agree on the best model, moving from log-likelihood to AIC to BIC will inevitably lead to increased 
tendency to select a model with fewer parameters due to the increasing penalty. 
Survival extrapolations influence the cost-effectiveness assessment through their estimation of 
either mean survival or restricted mean survival time (RMST). These outcomes are equivalent to life-
years used by NICE, which are scaled by quality of life utility values to estimate treatment effect in 
quality-adjusted life-years. RMST is the area under the survival model up to the time horizon of the 
economic model from the relevant STA. If a survival model predicts that all patients will have 
experienced an event on or before the upper bound of time applied in the RMST, then the RMST will 
equal the mean survival time. 
1.3 Objectives 
NICE technical support document (TSD) 14 contains recommendations issued by the NICE decision 
support unit for extrapolations of individual patient survival data [6]. In its recommendations, TSD14 
favours AIC and BIC over the use of the log-likelihood statistic, alongside consideration of the 
plausibility of extrapolations. Consequently, the review by Gallacher et al. found that 100% (n=28) of 
cancer STAs in 2017 used at least one of AIC and BIC when selecting a model for survival 
extrapolation [1]. However, it is unclear whether using AIC or BIC actually provides a benefit over 
log-likelihood in terms of accuracy of mean survival estimation, motivating this work. 
The aims of this paper are: 
- to demonstrate the performance of fitting parametric curves to trial data when estimating 
RMST, 
- to identify the dangers of selecting the incorrect model for extrapolation when estimating 
RMST, and 
- to identify whether there is any distinction between AIC, BIC and log-likelihood when 
estimating RMST  
2 Method 
In order to compare the three model selection methods in terms of extrapolation accuracy we 
conducted a simulation study, using the AIC, BIC and log-likelihood to select a model to many 
simulated datasets.  Data were generated from exponential, Weibull and generalised gamma 
distributions, chosen as these parameterisations routinely feature in health technology appraisals 
and contain different numbers of parameters capturing varying degrees of flexibility of the hazard 
function [1]. The parameters of these distributions and patterns of follow-up were based on four 
completed trials. The aim was not to generate scenarios that reproduced data identical to each of 
the trials or their hazard curves, but to obtain 12 scenarios where the parameters came from trials, 
and could be considered representative of evidence included in technology appraisals. 
We selected four trials that were pivotal in NICE STAs, covering a range of interesting scenarios each 
with a differing combination of sample size, follow-up time, and number of events observed [7-10], 
focusing on their experimental arms. A summary of the trials is in Table 2, including the time horizon 
of each appraisals economic model used as the upper bound for estimating RMST. Additional detail 
of the parameters used to generate each scenario can be found in Table S5 of the supplementary 
information. They are typical of phase III trials used in NICE technology appraisals, though 
characteristics will vary due to differences in diseases, prognosis, and outcome. The ARCHER 1050 
trial had 103 overall survival (OS) events observed from 227 patients with EGFR mutated non-small-
cell lung cancer receiving dacomitinib in 46 months of follow-up, demonstrating an increasing hazard 
rate over time. In KEYNOTE 045, 437 progression-free survival (PFS) events were experienced across 
542 second-line patients with advanced urothelial cancer in 18 months of follow-up, with the 
pembrolizumab PFS hazard rate clearly higher in the first two months of follow-up than for the 
remaining follow-up. APHINITY used the outcome of invasive disease-free survival, with 171 of the 
2400 patients who had previously had HER2-positive breast cancer experiencing events in the 
pertuzumab + trastuzumab arm in 48 months, with a constant rate of events observed. MURANO 
captured 15 OS events in 194 venetoclax + rituximab patients with relapsed or refractory chronic 
lymphocytic leukaemia in 38 months of follow-up, demonstrating a constant or decreasing hazard 
rate.   
The four trials could be divided into two categories, trials where median survival was reached 
according to the Kaplan-Meier plot (dacomitinib/ARCHER 1050 and pembrolizumab/KEYNOTE 045), 
and those where the median was not observed (pertuzumab/APHINITY and venetoclax/MURANO). 
The Kaplan-Meier curve for the novel intervention from each trial was digitised according to the 
method described by Guyot et al. in order to recreate individual patient-level data (IPD) [11]. Three 
different parametric models were fitted to each set of IPD to capture a variety of hazard profiles 
whilst maintaining a manageable number of simulation scenarios. Exponential, Weibull and 
generalised gamma distributions were chosen due to their varying number of parameters and 
hazard flexibility. All models were fitted using Broyden-Fletcher-Goldfarb-Shanno optimisation. The 
parameters from each of these 12 fitted models (that is, 12 scenarios) were first used to calculate 
the “true” RMST for each scenario and secondly to generate 10,000 sets of time-to-event data via 
the rexp(), rweibull() and rgengamma() commands included within the stats and flexsurv packages in 
R [12]. Patients were simulated as being more likely to be recruited later in the recruitment 
duration, imitating the expanding recruitment of multi-centre trials as more centres join a trial over 
time.   
From each simulated set of data two datasets were then created.  The first with complete data 
where every individual had an observed event time and the second with event times censored for 
some individuals mirroring the follow-up pattern observed in the actual trial. Censoring from 
incomplete follow-up was modelled by simulating a recruitment time for each patient from an 
exponentially increasing probability density function based on the recruitment period reported for 
each trial and a fixed trial end time given by the maximum follow-up time, with all patients without 
an event observed before this time considered to be censored. Additional censoring from loss to 
follow-up or withdrawal was modelled by generating censoring times for each patient from an 
exponential distribution with a low hazard rate. 
 
2.1 Analysis of simulated data 
To each simulated set of data we attempted to fit 8 parametric models: exponential, Weibull, log-
normal, log-logistic, gamma, generalised gamma, Gompertz and generalised F. The first seven 
models feature routinely in technology appraisals [1], and the generalised F can be considered as a 
generalisation of the generalised gamma [13]. The estimated value of RMST was recorded for each 
parametric model. Spline models were not included due to the additional specification required in 
selecting the optimal spline model. The best fitting model in each simulation according to each of 
AIC, BIC and log-likelihood was selected and the corresponding RMST recorded. Standard errors and 
confidence intervals around the RMST estimates are not easily obtained from fitted models, and do 
not capture the uncertainty around the suitability of the survival curve. Reliance on these estimates 
of uncertainty that originate from the observed data may underestimate the structural uncertainty. 
For example a confidence interval from a Weibull model will ignore the possibility the data could be 
better represented by a log-logistic model which may only become clear once data from extended 
follow-up is available..  The code used to simulate, fit models and store estimates can be accessed 
on https://github.com/daniel-g-92/goodness-of-fit-paper1. 
2.2 Performance Measures 
Bias of RMST estimates from the models was evaluated through calculation of the absolute and 
percentage difference of both the mean and median estimated RMST from the RMST value of the 
source distribution. Mean squared error (MSE), empirical standard error (EmpSE) and Monte-Carlo 
standard error (MCSE) of RMST estimates for all models were also measured, as defined by Morris et 
al. [14]. Coverage probability could not be estimated without confidence intervals of the individual 
RMST estimates. Instead, we provide an alternative measure, reporting the percentage of RMST 
estimates that fall within 10% of the target RMST value.  
3 Results 
3.1 Model fitting 
Only results from models that had successfully fitted without error or convergence warning were 
included in the analysis (supplementary information; Table S1). Successful model fitting rates were 
generally high, with only the trial scenarios of the generalised F and generalised gamma models 
having a success rate below 80%. The generalised F distribution often failed fitting to the 
pertuzumab data, fitting successfully in as few as 17% of runs. Due to the occasionally skewed 
distribution of the RMST estimates, the mean and median RMST estimates from the simulation runs 
are both presented. The Monte-Carlo standard errors were consistently minor compared to the 
RMST estimates, suggesting the number of simulations was suitable (Table 3 and S4). 
3.2 Model extrapolation without selection 
There were similarities between the results within the groups based on whether median survival 
times had been observed (dacomitinib/ARCHER 1050 and pembrolizumab/KEYNOTE 045) or not 
(pertuzumab/APHINITY and venetoclax/MURANO), and so for brevity we describe only results for 
pembrolizumab and pertuzumab trials here, with results for the other trials included in the 
supplementary information.  
3.2.1 Pembrolizumab/KEYNOTE 045 
For the exponential and Weibull scenarios of complete follow-up, most models fitted equivalently 
well. The exponential, Weibull, gamma, generalised gamma, Gompertz and generalised F were all 
accurate, producing estimations of RMST within 10% of the true RMST in at least 80% of simulations 
and having the lowest EmpSE (Supplementary information Table S4). Despite the maturity of the 
data, the log-normal and log-logistic models produced biased estimates of RMST for these scenarios, 
with the RMST estimates falling within 10% of the true value in 4.4% of simulations or fewer. The 
mean estimates of RMST from the log-normal and log-logistic models overestimated by as much as 
70% (log-logistic fitted to Weibull pembrolizumab data, Table S4), which corresponded to a 
difference of 4 months additional overestimated benefit. MSE was low for all models apart from log-
normal and log-logistic.  
In the generalised gamma scenario of complete follow-up, the estimates of RMST showed 
considerable variation, with  the generalised gamma and generalised F models being the best fitting, 
with the least bias, lowest MSE and EmpSE, and the most estimates of RMST within 10% of the true 
RMST . The log-logistic, log-normal and Gompertz models were the worst fitting, with 3% to 7% of 
simulations producing estimates of RMST within 10% of the true value, and their mean estimates of 
RMST underestimating by 28% to 30%. The gamma and exponential curves had extremely high 
MSEs, and produced the most heavily biased estimates.  
For the exponential scenario of trial follow-up, the exponential model was the most reliable 
predictor of RMST, with estimates falling within 10% of the true value in 86% of simulations, but was 
closely followed by the Weibull (84%) and gamma (85%) models. The estimates from each of these 
three models were unbiased and associated with the lowest MSE and EmpSE. The log-normal and 
log-logistic were again biased with their mean estimates of RMST overestimating by 62% and 82% 
respectively, and were associated with considerably higher MSE and EmpSE. This poor performance 
of the log-normal and log-logistic models was repeated in the Weibull scenario of trial follow-up, 
where the respective mean estimates of RMST were 93% and 114% over. However, the Gompertz 
model also produced biased estimates of RMST in the Weibull scenario, overestimating by 151%. 
Here the Weibull model was the least biased, but with the gamma model having slightly lower MSE 
and EmpSE. 
All models produced estimates of RMST that varied highly for the generalised gamma scenario of 
trial follow-up. MSEs for all models were considerably higher than for the Weibull and exponential 
scenarios. The generalised gamma fit produced the least biased and most accurate estimates of 
RMST, with its estimates falling within 10% of the true value in 26% of simulations and mean 
estimate of RMST only 5% higher than the true value. The generalised F model was second best with 
slightly higher bias (+13%) and just 24% of estimates falling within the 10% range. For most other 
fitted models, 0% of RMST estimates fell within the 10% range. The mean RMST estimate for 
exponential, Weibull, log-normal, log-logistic and gamma models all severely underestimated RMST, 
ranging from 39% to 57% below the true value. In contrast, the estimate from the Gompertz model 
overestimated by 152%.  
3.2.2 Pertuzumab/APHINITY 
For all three scenarios of complete follow-up, the majority of the models produced accurate 
estimates of RMST. The worst fitting model was the log-normal, but even in the exponential 
scenario, where it was the least accurate, its estimates of RMST still fell within 10% of true value in 
98% of simulations and its mean RMST estimate was 8% less than the true RMST. In the pertuzumab  
scenarios of full follow-up, which had a much larger sample size than the pembrolizumab trial, the 
magnitude of the bias from any fitted model never exceeded 7%. 
For the exponential scenario of trial follow-up, the exponential model was superior, with 0% bias, 
the lowest MSE and EmpSE, and with 99% of RMST estimates falling within 10% of the true value. 
The least accurate models were the Gompertz, generalised F and log-normal, with 13%, 3% and 0% 
of their respective estimates falling within 10% of the true RMST. Log-normal RMST estimates were 
the most biased with the mean estimate 26% above the true value.  
The models for the Weibull and generalised gamma pertuzumab scenarios were almost identical 
(Figure 3), and hence had similar results. The Gompertz, generalised F and log-normal models 
performed poorly across these two scenarios with less than 8% of the estimates falling within 10% of 
the true RMST and bias of up to 38%. The Weibull, generalised gamma and generalised F models 
were unbiased in both scenarios The gamma curve was associated with the lowest MSE and EmpSE 
and highest percentage of estimates falling within the 10% range. Both MSE values and EmpSE were 
much higher for all models in the trial scenarios than the scenarios of complete follow-up.  
3.3 Model Selection 
For all scenarios of complete follow-up, the models preferred by each of AIC, BIC and log-likelihood 
all produced near identical, unbiased estimates of RMST though BIC was slightly superior in the 
majority of cases (Table S4). For most scenarios of complete follow-up, the methods had similar 
estimates of MSE, MCSE and EmpSE. Only in the exponential scenario of pertuzumab were the 
methods distinguishable, with models preferred by BIC having the lowest EmpSE and MSE.   
3.3.1 Pembrolizumab/KEYNOTE 045 
In the exponential scenario of trial follow-up, AIC selected the exponential model in 71% of 
simulations, compared to 96% for BIC and 0% for log-likelihood (Figure 4a). Models preferred by BIC 
were associated with the least bias (+3%), lowest MSE and had most number of estimates falling 
within the 10% range (84%). Models preferred by log-likelihood had the highest bias of the three 
selection methods (+10%) and the lowest percentage of estimates within the 10% range (61%), but 
the lowest EmpSE. Models preferred by BIC were only slightly outperformed by selection of the 
exponential model each time.  
For the Weibull scenario of trial follow-up, the Weibull model was preferred by AIC in 34% of 
simulations. BIC and log-likelihood preferred Weibull in 26% and 0% of simulations respectively 
(Figure 4b). Models with the highest log-likelihood were associated with the least bias (+20%), 
lowest MSE and EmpSE but had the lowest percentage of estimates within 10% of the true value 
(49%). Models preferred by BIC had the highest percentage of estimates within the range (66%). 
The methods of model selection were outperformed by repeated selection of either the Weibull or 
gamma model, which had less bias and more reliable RMST estimates, suggesting the selection 
methods could be improved.  
In the generalised gamma scenario of trial follow-up, AIC favoured the generalised gamma model in 
94% of simulations, compared to 92% and 62% for BIC and log-likelihood respectively (Figure 4c). 
Models preferred on the basis of BIC were associated with the least bias (+4%), lowest MSE and 
EmpSE and most number of estimates within 10% of the true RMST (26%). The performance of the 
other two selection methods was similar. Selecting the generalised gamma curve every time would 
have only had negligible improvement over relying on the methods of model selection, suggesting 
the selection methods did well. 3.3.2 Pertuzumab/APHINITY 
From the simulations of the exponential scenario of trial follow-up, AIC selected the exponential 
model in 65% of the time, compared to 94% and 0% for BIC and log-likelihood respectively (Figure 
4d). Models with the lowest BIC were associated with the lowest EmpSE and MSE, and highest 
percentage of estimates in the 10% range, but models preferred by AIC had slightly less bias (+2%). 
Selecting the exponential model every time would have offered a small improvement over using BIC 
preferred models..  
In the Weibull scenario, AIC, BIC and log-likelihood preferred a Weibull  model in 7%, 1% and 1% of 
simulations respectively (Figure 4e). Models with the lowest BIC had the lowest MSE, EmpSE and the 
largest number of estimates in the 10% range (25%), however models preferred by AIC had slightly 
less bias (-3%). 
Selecting the Weibull or gamma models would have considerably increased the percentage of 
estimates falling within the 10% range but had little impact on bias.  
For the generalised gamma scenario, AIC and BIC favoured the exponential (42% and 86% 
respectively; Figure 4f) over the generalised gamma model (5% and 4% respectively), whereas the 
log-likelihood favoured the generalised gamma in 53% of simulations. Models preferred on the basis 
of AIC featured the least bias (-3%) and had the largest number of estimates within the 10% range 
(17.8%). Models preferred by BIC were associated with the lowest MSE and EmpSE. . . Selecting the 
generalised gamma model in every simulation would have had marginal improvements over using a 
method of model selection, however selecting the gamma model each time would significantly 
increase the percentage of estimates falling within 10% of the true value (65%). 
3.3.3 Agreement of AIC, BIC and log-likelihood 
We also explored whether greater reliability from AIC, BIC and log-likelihood preferred models might 
be obtained if the approaches agreed on the same model. In the majority of scenarios explored, 
there was almost no agreement on the preferred model between log-likelihood and BIC. 
For the pembrolizumab exponential scenario, RMST estimates were no more accurate when AIC and 
BIC agreed on the best model. Of the 7471 simulations where the two criteria agreed on the model, 
6227 simulations fell within 10% of the true RMST value (83%), which was not an improvement on 
selecting the exponential model each time (86%), or on the BIC alone (84%), but did improve on the 
AIC alone (77%). Similar results were observed for the other source distributions and trials. 
3.4 Summary of Results 
If a parametric model is selected which does not resemble the underlying survival distribution, it is 
likely to result in bias, even if data are complete.  
Simple hazard behaviour (exponential/constant) can be captured well from data simulating trial 
follow-up, but Weibull and generalised gamma often cannot.  
In the scenarios considered, BIC was generally superior for selecting models which resulted in 
accurate and unbiased estimates of RMST when follow-up was suitably mature. 
With immature data, all three methods can be biased in their model selection, leading to biased 
estimates of RMST. 
In the scenarios of trial follow-up, the larger EmpSE associated with the models by each of the 
selection methods, and the generalised gamma and generalised F models suggest that the remains 
considerable variation in the RMST estimates generated by these methods. 
4 Discussion 
We have presented a range of scenarios demonstrating the dangers of extrapolating using 
parametric models and relying heavily on AIC, BIC and log-likelihood for model selection. The 
incorrect choice of model can result in large bias but even the model matching the underlying 
distribution can be associated with large variability in the RMST estimates, suggesting that  
extrapolating across population lifetimes may be a less than ideal tool for assessing the utility of 
health technologies. Model selection based solely on goodness of fit statistics has been shown to 
lead to bias, due to the selection of the incorrect model. Incorporating some measure of plausibility 
may improve this by removing implausible models from consideration. BIC had a tendency to select 
the exponential model, which is the model with the fewest parameters, even when the source 
distribution was Weibull or generalised gamma. Whereas the log-likelihood favoured the generalised 
gamma and generalised F models, with the largest number of parameters, across all scenarios. When 
the follow-up was more mature, BIC appeared superior to the other methods, even when the source 
distributions contained multiple parameters. This could be influenced by the source distributions 
and parametric models considered, but could be generalisable to scenarios beyond this simulation 
study. This result could also be driven by the fact that the set of candidate models included the true 
model. BIC has been shown to work better when this is the case, whereas AIC does not seek to 
identify the true model, but the best predicting model.  
It is clear that reliance solely on statistical measures of goodness-of-fit can result in severe bias and 
incorrect estimation of RMST even when two or more measures might agree on the optimal model, 
and it is reassuring that model plausibility is also usually considered in practice, though not always 
[2]. Our scenarios of trial follow-up suggested that the models preferred by the selection methods 
were often associated with significantly higher MSEs than the best parametric model, suggesting 
there is room for improvement over AIC and BIC when selecting models for extrapolation. We have 
shown that the difference in the underlying assumptions of the shapes of the models is an important 
consideration, given that the log-normal, log-logistic  and Gompertz models often provided markedly 
difference estimates of RMST compared to the other parametric forms, particularly in the scenarios 
of trial follow-up. Of course, if we repeated our simulation study using these distributions to 
generate scenarios, then we would anticipate them to perform much better. We recommend that 
pharmaceutical companies provide very rigorous justification for their preferred model, perhaps pre-
specifying the model for extrapolation, including evidence of why the long-term hazard behaviour 
can be considered plausible for their intervention. We have demonstrated that selection should not 
be based on goodness-of-fit statistics alone, and health technology assessors should be suspicious 
and perhaps automatically reject cases where no further consideration beyond information criteria 
is made. Even when follow-up is complete, selecting the incorrect parametric model may result in a 
biased estimate of mean survival. 
We have shown that trial follow-up typical of that used in NICE technology appraisals can be 
insufficient for reliable extrapolation, even when the model selected from extrapolation matches 
that of the underlying sample distribution. It is concerning to see how the models and methods of 
model selection struggled with these relatively simple scenarios of time-to-event data, where all 
events came from a single distribution. As medical technologies advance and we move towards 
personalised medicine it will be increasingly common to require greater flexibility than that which is 
offered by a single parametric model. We anticipate that the accuracy and reliability of 
extrapolations will only deteriorate as data come from more complex underlying hazard behaviours, 
especially when the behaviour of the hazard rate is expected to differ beyond the observed period. 
Despite the fact that the scenarios considered here were relatively simple, all using single parametric 
distributions as a source, the fitted models often contained considerable uncertainty. It is likely that 
real world data will not follow such simple forms, and it is  possible that using the selection methods 
and parametric models may perform even worse in terms of either bias or uncertainty. Inevitably, 
there will often be key differences between high-risk patients whose events are observed, and the 
low risk patients remaining at risk after typical follow-up of a phase III trial, meaning the observed 
hazard rate behaviour will not be representative of the hazard rate beyond the observed period. 
Even if the right model is selected, it is possible that the tail data will not contain enough 
information to accurately estimate the parameters. Alternatively, the hazard rate may deviate from 
the shape of all of the candidate models. Whilst models incorporating cure proportions or time-
varying hazard ratios sometimes feature in health technology appraisals, the data are likely to be 
insufficient to accurately estimate the parameters of these more complex models to provide reliable 
extrapolations. Reliance on goodness-of-fit to observed data will only be reliable when the 
unobserved hazard rate is linked to the observed behaviour in a way that is captured by at least one 
of the candidate parametric models. By definition, each of AIC, BIC and log-likelihood assess model 
fit solely on the observed period, explaining why the performance of the methods improves as the 
length of follow-up increases. The methods of selection do not account for the uncertainty beyond 
the observed follow-up period. The suitability of parametric model extrapolation and goodness-of-fit 
statistics will surely vary across diseases and the patterns of treatment response. 
Given the generally high levels of uncertainty when extrapolating (which will still exist when 
plausibility is taken into account) it raises the question of whether NICE should seek an alternative 
approach rather than rely on potentially inaccurate and unreliable extrapolations to decide whether 
to fund new interventions. If a NICE appraisal committee decides to focus on a particular subgroup 
of patients, rather than the licensed population which would usually be represented in the trial, the 
relevant survival data will contain even less information, inflating the uncertainty associated with 
RMST. Perhaps greater consideration of extrapolation should be made when designing clinical trials. 
There may be plenty of evidence of the long term outcomes for a population receiving a comparator, 
in which case more patients could be recruited into the intervention arm of a trial, maximising the 
opportunity to collect information necessary to obtain the most reliable extrapolation. If this is not 
feasible, perhaps recommendations should be made on a temporary basis, with a final decision on 
approval and pricing only made after a certain degree of follow-up has been observed, such as the 
current operation of the Cancer Drugs Fund in England. Alternative approaches that assess benefit 
on observed periods may encourage longer follow-up and reduce the uncertainty for decision-
makers, but would probably slow down access to new therapies. 
Whilst the exponentially distributed trial data generally contained enough information for its 
underlying hazard to be captured by the fitted exponential models, the same is not true for the 
generalised gamma models. This questions whether it is appropriate to select a generalised gamma 
or generalised F model for extrapolation from typical follow-up of a phase III trial, given that their 
RMST estimate is not likely to be within 10% of the true RMST, as seen in three of the four modelled 
trials. This could be true even if it is known that the generalised gamma is representative of the 
population’s survival profile, and may be driving the superiority of BIC. This may mean that simpler 
models should be preferred when data are particularly immature. The curves with more parameters 
also demonstrated overfitting to data simulated from a simpler distribution. The convergence issues 
experienced with the generalised F may explain its lower popularity in NICE appraisals. Heinze et al. 
have discussed the related concept of events-per-variable [15]. 
It is interesting how the estimates from the pertuzumab/APHINITY trial were associated with the 
most uncertainty, yet the company in this appraisal extrapolated using a parametric model as done 
in this study. Meanwhile, in the venetoclax appraisal, the company did not extrapolate their 
outcome, citing insufficient follow-up. It is unclear what truly motivates a company to select a 
method of extrapolation, (e.g. whether to use parametric models or not) but it is possible that there 
is insufficient consideration of associated uncertainty, with greater emphasis placed on the resulting 
incremental cost-effectiveness ratio (ICER). 
Aside from the exponential distribution, all models have multiple parameters. It is possible that any 
bias or uncertainty is associated more strongly with some parameters than others or that the 
uncertainty associated with one parameter is more influential on the estimates of RMST. If this was 
true, it could alter the way that uncertainty around survival is accounted for in technology 
appraisals. Probabilistic sensitivity analyses (PSA) are inconsistent with their inclusion of survival 
parameters and commonly exclude them [1]. Identification and inclusion of key parameters could 
improve the uncertainty captured in PSAs. Ideally a PSA would also include the uncertainty around 
the choice of model, however there is no well-established method for incorporating structural 
uncertainty into a PSA.  
Strengths 
The strengths of this study include that it has captured the characteristics of four independent 
clinical trials that were highly influential in NICE technology appraisals. We have captured a range of 
different time-to-event outcomes, each with its unique combination of events, follow-up length and 
hazard profile. The methods included are representative of current practice and clear issues are 
identified. It is highly relevant to decision makers and disease modellers.  
Limitations 
A simulation study of this kind is unable to verify the plausibility of every extrapolation or assess the 
visual fit of multiple models through a comparison to the Kaplan-Meier or cumulative hazard plot, 
and so we did not consider plausibility in our study. Both visual fit and extrapolation plausibility are 
commonly used alongside information criterion when selecting a parametric model in practice as 
recommended by two reviews [1, 2], and may improve the application of information criterion when 
used in combination. They could rule out clearly implausible extrapolations for a specific disease or 
indication, preventing these models from being selected by AIC and BIC. Similarly, the issues around 
convergence for certain models in particular scenarios may be introducing bias into the analysis. The 
results are also dependent on the models used to generate each scenario.  
We have used RMST rather than overall mean survival time with the restriction applied 
corresponding to the time horizon used in each appraisal’s economic analysis. Following this 
truncation, the bias of RMST estimates for certain models may be underestimated. If we had allowed 
the time horizon to vary based on the predictions of each model, we would likely observe even more 
uncertainty in the estimates of RMST due to the tails of models such as the log-normal being allowed 
to carry on for much longer. 
We used an arbitrary measure of 10% distance from the true RMST to measure accuracy of the 
RMST predictions. This allowed some degree of comparison across the different trials, but may still 
be inappropriate due to the wide range in underlying RMSTs. For example, there may be much more 
uncertainty in the ICER in the venetoclax study, despite more of its RMST estimates falling within the 
10% threshold across the various scenarios.  
We have only considered RMST from single arms of trials. Whilst potential bias should always be 
avoided, its effect may be reduced if the bias is roughly equivalent on both arms of a trial, hence 
having a minimal effect on the estimate of incremental differences in RMST. However, the broad 
uncertainty demonstrated in these simulations offer no guarantees that bias will be evenly 
distributed across trial arms. The level of uncertainty observed in the extrapolations also raises the 
question of whether extrapolation is an acceptable approach to estimating treatment benefit.  
Only the characteristics of four trials were considered in this study. It is possible that the usefulness 
of AIC and BIC may vary based on the hazard profile, the selection of models considered and the 
degree of follow-up. 
We have only simulated from three parametric distributions. Real world data may come from other 
distributions, or may not be well represented by a parametric curve. Similarly, it is unclear whether 
alternatives to parametric modelling, such as combining trial data with external data [16], or use 
Bayesian model averaging [17], may improve RMST predictions.  
Relying solely on estimates of RMST alone, without assessment of plausibility at certain benchmarks, 
could mean that a seemingly unbiased estimate of RMST is the result of a combination of over- and 
under-prediction. The consequences of this could be significant in economic modelling due to 
additional considerations such as discounting and age related disutilities meaning that it is important 
to capture when treatment benefit occurs, rather than just overall absolute benefit.  
 
Conclusion 
This study demonstrates issues with parametric extrapolation of time-to-event data and the reliance 
on AIC and BIC to select a preferred model. We show that data from trials used in NICE technology 
appraisals is often inadequate to obtain an accurate and unbiased extrapolation. In scenarios of 
mature trial follow-up, BIC was generally superior to AIC and log-likelihood. Further work is needed 
to identify when data are mature enough to provide acceptable levels of certainty around survival 
extrapolations.  
 
Recommendations 
Consider underlying hazard assumption, as assuming the incorrect model can result in large biases. 
All model selection methods occasionally led to preferred models with extremely high estimates of 
mean survival. Care should be taken to also consider plausibility of estimates, and to not solely rely 
on statistical goodness of fit when selecting a model.  
BIC appears superior for model selection when data are sufficiently mature. 
Restricted follow-up can contain too little information for a reliable model of a multi-parameter 
model to be estimated and extrapolated. 
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Table 1: Summary of paper following ADEMP guidelines [14] 
ADEMP Category Response 
Aims To demonstrate the performance of fitting 
parametric curves to time-to-event data when 
estimating restricted mean survival time (RMST). 
To identify the dangers of selecting the incorrect 
model for extrapolation when estimating RMST. 
To identify whether there is any distinction 
between AIC, BIC and log-likelihood when 
estimating RMST. 
Data generating mechanism Data were repeatedly sampled from exponential, 
Weibull and generalised gamma distributions 
using parameters estimated from fitting models 
to recreated data from four phase III trials using 
a frequentist framework.  
Methods Data were censored using trial-specific 
parameters to replicate the maturity of data 
when the technologies were considered for 
reimbursement. Eight parametric curves were 
fitted to the data and their RMST estimates and 
goodness-of-fit statistics were captured. The 
models preferred by each of AIC, BIC and log-
likelihood were compared. 
Estimand RMST  
Performance Measures Bias, empirical SE, mean-squared error, Monte-
Carlo standard error 
 
 Table 2: Summary of clinical trials included in the simulation 
Intervention 
Trial 
Indication 
Outcome 
no. observed events 
/ no. patients in arm 
(%) 
Median 
Survival 
Maximum 
Follow-up 
Description of 
observed hazard 
behaviour 
How company 
modelled outcome in 
technology appraisal 
Time Horizon used in 
economic model and 
to calculate RMST 
Censoring parameters 
Dacomitinib 
ARCHER 1050 
Treatment for untreated 
EGFR-positive non-small 
cell lung cancer 
Overall survival 
 
103/227 (45.4%) 
34.1 
months 
46 months Increasing hazard 
rate. 
Used a hazard ratio from 
a fractional polynomial 
model and applied to a 
generalised gamma 
extrapolation of a 
comparator. 
15 years (180 months) Recruitment period: 12 
months 
Recruitment λ: 0.2 
Loss to follow up λ: 
0.002  
Max follow up: 18 
months 
Pembrolizumab 
KEYNOTE-045 
Treatment for previously 
treated advanced or 
metastatic urothelial 
cancer 
Progression-free 
survival 
 
437/542 (79.2%)† 
 
2.1 
months 
18 months A sudden decrease 
in hazard rate at 2 
months. 
Used an exponential 
curve to data beyond 21 
weeks.  
35 years (420 months) Recruitment period: 21 
months 
Recruitment λ: 0.1 
Loss to follow up λ: 
0.002   
Max follow up: 48 
months 
Pertuzumab + 
Trastuzumab 
APHINITY 
Adjuvant treatment of 
early HER2-positive breast 
cancer 
Invasive disease free 
survival 
 
171/2400 
(7.1%) 
Not 
reached 
48 months Constant hazard 
rate 
Used a log-logistic 
extrapolation. 
52 years (624 months) Recruitment period: 23 
months 
Recruitment λ: 0.1 
Loss to follow up λ: 
0.002   
Max follow up: 46 
months 
Venetoclax + Rituximab 
MURANO 
Treatment for relapsed or 
refractory chronic 
lymphocytic leukaemia 
Overall survival 
 
15/194  
(7.7%) 
Not 
reached 
38 months Constant or 
decreasing hazard 
rate. 
Used a Weibull curve 
fitted jointly to both 
arms of the trial for both 
PFS and OS data 
simultaneously. 
20 years (240 months) Recruitment period: 18 
months 
Recruitment λ: 0.1 
Loss to follow up λ:  
0.002 
Max follow up: 38 
months 
† numbers are for whole trial, not reported by arm. 
Table 3: Results for trial follow-up scenarios 
Drug/ Trial/ 
Outcome/ 
Source 
distribution 
True 
RMST 
(+/- 10%) 
Measure Results 
   Exponential Weibull Log-normal Log-logistic Gamma Generalised gamma Gompertz Generalised F Model with lowest AIC Model with lowest BIC Model with highest 
log-likelihood 
Pembrolizumab/ 
KEYNOTE 045/ 
PFS/ Exponential 
 
5.6 (5.0 - 
6.2) 
Mean [bias] 
(5%, 95%) 
Median 
MSE 
MCSE 
EmpSE 
% within 10% 
5.61  [+0.01, +0%] 
(5.01, 6.28) 
5.60 [-0.00, -0%] 
0.15  
0.00  
0.39 
85.6% 
5.62 [+0.02, +0%] 
(4.99, 6.33) 
5.59 [-0.01, -0%] 
0.17  
0.00  
0.41 
83.6% 
9.10 [+3.50, +62%] 
(7.22, 11.58) 
8.89 [+3.29, +59%] 
14.12  
0.01  
1.38 
0.2% 
10.19 [+4.59, +82%] 
(8.32, 12.47) 
10.06 [+4.46, +80%] 
22.76  
0.01  
1.30 
0.0% 
5.61 [+0.01, +0%] 
(5.00, 6.30) 
5.59 [-0.01, -0%] 
0.16  
0.00  
0.40 
84.8% 
5.66 [+0.06, +1%] 
(4.97, 6.54) 
5.61  [+0.01, +0%] 
0.24  
0.00  
0.48 
78.4% 
6.11 [+0.51, +9%] 
(4.96, 8.86) 
5.63  [+0.03, +1%] 
4.72  
0.02  
2.11 
70.3% 
6.18 [+0.58, +10%] 
(5.04, 8.56) 
5.84 [+0.24, +4%] 
1.81  
0.01  
1.21 
60.0% 
5.97 [+0.37, +7%] 
(4.98, 8.75) 
5.62 [+0.02, +0%] 
3.05  
0.02  
1.71 
76.9% 
5.74 [+0.14, +3%] 
(5.00, 6.37) 
5.60 [-0.00, -0%] 
1.90  
0.01  
1.37 
83.7% 
6.17 [+0.57, +10%] 
(5.03, 8.58) 
5.83 [+0.23, +4%] 
1.91  
0.01  
1.26 
60.8% 
Pembrolizumab/ 
KEYNOTE 045/ 
PFS/ Weibull 
 
5.8 (5.2 - 
6.4) 
Mean [bias] 
(5%, 95%) 
Median 
MSE 
MCSE 
EmpSE 
% within 10% 
5.51 [-0.33, -6%] 
(4.87, 6.18) 
5.49 [-0.35, -6%] 
0.27  
0.00  
0.40 
71.0% 
5.87 [+0.02, +0%] 
(5.09, 6.75) 
5.84 [-0.01, -0%] 
0.26  
0.01  
0.51 
76.1% 
11.25 [+5.41, +93%] 
(8.41, 14.94) 
11.00  [+5.16, +88%] 
33.33  
0.02  
2.01  
0.0% 
12.48 [+6.64, +114%] 
(9.83, 15.65) 
12.33  [+6.49, +111%] 
47.22  
0.02  
1.78 
0.0% 
5.73 [-0.11, -2%] 
(5.02, 6.50) 
5.70 [-0.14, -2%] 
0.22  
0.00  
0.46 
77.9% 
5.93 [+0.09, +1%] 
(5.03, 7.10) 
5.85  [+0.00, +0%] 
0.43  
0.01  
0.65 
68.1% 
14.64 [+8.80, +151%] 
(5.38, 35.62) 
11.14  [+5.30, +91%] 
180.25 
0.10  
10.14 
19.1% 
6.86 [+1.02, +17%] 
(5.15, 10.90) 
6.25  [+0.40, +7%] 
4.93  
0.02  
1.97 
48.0% 
8.12 [+2.28, +39%] 
(5.08, 22.58) 
5.92  [+0.08, +1%] 
46.29  
0.06  
6.41 
59.9% 
7.79 [+1.95, +33%] 
(5.00, 23.65) 
5.77 [-0.08, -1%] 
47.98  
0.07  
6.65 
65.6% 
6.99 [+1.15, +20%] 
(5.14, 11.27) 
6.23  [+0.39, +7%] 
8.89  
0.03  
2.75 
49.0% 
Pembrolizumab/ 
KEYNOTE 045/ 
PFS/ Generalised 
gamma 
 
12.0 
(10.8 - 
13.2) 
Mean [bias] 
(5%, 95%) 
Median 
MSE 
MCSE 
EmpSE 
% within 10% 
5.16 [-6.84, -57%] 
(4.52, 5.84) 
5.14 [-6.86, -57%] 
46.95  
0.00  
0.40 
0.0% 
5.22 [-6.78, -56%] 
(4.53, 6.00) 
5.19 [-6.80, -57%] 
46.14  
0.00  
0.45 
0.0% 
6.16 [-5.84, -49%] 
(5.07, 7.44) 
6.10 [-5.90, -49%] 
34.61  
0.01  
0.73  
0.0% 
7.31 [-4.69, -39%] 
(5.84, 9.04) 
7.23 [-4.76, -40%] 
22.93  
0.01  
0.98 
0.1% 
5.12 [-6.88, -57%] 
(4.46, 5.84) 
5.10 [-6.90, -58%] 
47.52  
0.00  
0.42 
0.0% 
12.58  [+0.58, +5%] 
(7.67, 19.23) 
12.05  [+0.05, +0%] 
13.38  
0.04  
3.61 
26.3% 
30.22  [+18.23, +152%] 
(9.46, 54.73) 
29.04 [+17.05, +142%] 
524.08 
0.14  
13.85 
3.8% 
13.50  [+1.51, +13%] 
(7.96, 20.85) 
12.98  [+0.98, +8%] 
18.47  
0.04  
4.03 
23.8% 
12.83  [+0.84, +7%] 
(7.69, 19.93) 
12.26  [+0.26, +2%] 
15.30  
0.04  
3.82 
25.4% 
12.45  [+0.45, +4%] 
(6.27, 19.32) 
12.08  [+0.08, +1%] 
15.17  
0.04  
3.87 
25.8% 
13.48  [+1.48, +12%] 
(7.93, 20.82) 
12.97  [+0.97, +8%] 
18.41  
0.04  
4.03  
23.9% 
Pertuzumab/ 
APHINITY/ IDFS/ 
Exponential 
 
376.8 
(339.1 - 
414.5) 
Mean [bias] 
(5%, 95%) 
Median 
MSE 
MCSE 
EmpSE 
% within 10% 
377.08  [+0.24, +0%] 
(353.71, 401.26) 
377.13  [+0.29, +0%] 
207.85 
0.14  
14.42 
99.1% 
373.33 [-3.51, -1%] 
(311.12, 429.13) 
375.14 [-1.70, -0%] 
1299.50 
0.36  
35.88 
70.7% 
474.94  [+98.10, +26%] 
(444.34, 502.29) 
475.73 [+98.89, +26%] 
9936.52 
0.18  
17.69 
0.1% 
409.19 [+32.35, +9%] 
(363.46, 450.91) 
410.28 [+33.43, +9%] 
1754.38 
0.27  
26.61 
55.7% 
374.54 [-2.31, -1%] 
(321.78, 424.14) 
375.31 [-1.54, -0%] 
967.52 
0.31  
31.02 
77.4% 
377.52 [+0.68, +0%] 
(249.62, 489.12) 
385.11 [+8.27, +2%] 
7044.03 
0.87  
83.93 
28.8% 
357.48 [-19.36, -5%] 
(149.15, 540.86) 
373.90 [-2.95, -1%] 
18922.31 
1.36  
136.20 
13.2% 
359.51 [-17.34, -5%] 
(48.74, 517.28) 
420.89  [+44.05, +12%] 
24553.06 
3.67  
155.78 
3.2% 
367.97 [-8.87, -2%] 
(117.63, 487.51) 
379.14  [+2.30, +1%] 
10148.39 
1.00  
100.35 
67.3% 
361.49 [-15.35, -4%] 
(241.18, 401.84) 
376.04 [-0.80, -0%] 
5463.82 
0.72  
72.31 
93.1% 
362.26 [-14.58, -4%] 
(117.63, 512.31) 
396.59  [+19.74, +5%] 
15976.12 
1.26  
125.56 
26.3% 
Pertuzumab/ 
APHINITY/ IDFS/ 
Weibull 
 
338.7 
(304.8 - 
372.6) 
Mean [bias] 
(5%, 95%) 
Median 
MSE 
MCSE 
EmpSE 
% within 10% 
381.15  [+42.49, +13%] 
(356.83, 405.38) 
381.00  [+42.35, +13%] 
2021.77 
0.15  
14.70 
28.1% 
336.85 [-1.81, -1%] 
(270.45, 400.14) 
338.09 [-0.57, -0%] 
1562.08 
0.39  
39.48 
60.3% 
459.73  [+121.07, +36%] 
(425.61, 491.04) 
460.53 [+121.88, +36%] 
15055.39 
0.20  
19.92 
0.0% 
382.73  [+44.08, +13%] 
(333.71, 429.59) 
383.57 [+44.91, +13%] 
2793.72 
0.29  
29.17 
34.9% 
345.42  [+6.77, +2%] 
(291.58, 399.12) 
345.62  [+6.97, +2%] 
1115.72 
0.33  
32.71 
68.4% 
340.62  [+1.97, +1%] 
(191.83, 476.34) 
348.60  [+9.94, +3%] 
9878.10 
1.04  
99.37 
19.9% 
234.05 [-104.60, -31%] 
(117.91, 481.43) 
189.75 [-148.90, -44%] 
24065.06 
1.15  
114.56 
7.6% 
336.43 [-2.22, -1%] 
(48.99, 504.25) 
398.36  [+59.70, +18%] 
23070.07 
3.60  
151.91 
2.1% 
326.83 [-11.83, -3%] 
(54.09, 461.40) 
373.29  [+34.63, +10%] 
15028.77 
1.22  
122.03 
23.0% 
353.99  [+15.33, +5%] 
(54.09, 410.03) 
379.16  [+40.51, +12%] 
8354.30 
0.90  
90.11 
25.4% 
311.79 [-26.87, -8%] 
(54.09, 481.47) 
356.16  [+17.50, +5%] 
18870.91 
1.35  
134.73 
13.9% 
Pertuzumab/ 
APHINITY/ IDFS/ 
Generalised 
gamma 
 
333.5 
(300.2 -  
366.9) 
Mean [bias] 
(5%, 95%) 
Median 
MSE 
MCSE 
EmpSE 
% within 10% 
381.40  [+47.87, +14%] 
(357.92, 405.76) 
381.06  [+47.53, +14%] 
2504.79 
0.15  
14.59 
15.9% 
336.71  [+3.18, +1%] 
(269.31, 400.80) 
337.99  [+4.46, +1%] 
1595.29 
0.40  
39.82 
58.9% 
459.82  [+126.29, +38%] 
(425.58, 490.91) 
460.78  [+127.25, +38%] 
16347.79 
0.20  
19.99 
0.0% 
382.65  [+49.12, +15%] 
(332.78, 429.96) 
383.63  [+50.09, +15%] 
3278.31 
0.29  
29.42 
28.5% 
345.40  [+11.87, +4%] 
(290.55, 399.17) 
345.59  [+12.05, +4%] 
1227.17 
0.33  
32.96 
65.2% 
337.86  [+4.32, +1%] 
(185.86, 477.76) 
343.81  [+10.28, +3%] 
10242.31 
1.05  
101.12 
19.7% 
233.09 [-100.44, -30%] 
(117.75, 486.77) 
188.28 [-145.25, -44%] 
23496.66 
1.16  
115.80 
7.0% 
335.31  [+1.78, +1%] 
(49.09, 501.25) 
392.29 [+58.76, +18%] 
22273.48 
3.57  
149.28 
2.0% 
325.00 [-8.54, -3%] 
(53.25, 462.89) 
372.56  [+39.03, +12%] 
15274.16 
1.23  
123.30 
17.8% 
352.75  [+19.22, +6%] 
(53.25, 409.24) 
379.14  [+45.60, +14%] 
8806.67 
0.92  
91.86 
14.8% 
309.11 [-24.42, -7%] 
(53.25, 483.50) 
350.94  [+17.41, +5%] 
19095.08 
1.36  
136.02 
12.1% 
AIC: Akaike information criterion; BIC: Bayes information criterion; EmpSE: empirical standard error; IDFS: invasive disease free survival; MCSE: Monte-Carlo standard error; MSE: mean squared error; OS: overall 
survival; PFS: progression free survival. 
Shaded cells indicate model or model selection method with lowest MSE. Bold cells indicate model distribution matches source distribution. 
 
  
 
Figure 1: Nesting relationships among models fitted in this simulation study 
 
 
 
 Figure 2: Observed and predicted cumulative hazard for pembrolizumab and dacomitinib trials 
 
 Figure 3: Observed and predicted cumulative hazard for pertuzumab and venetoclax trials 

 
Figure 4: Distribution of curve selection 
 
a: exponential pembrolizumab scenario; b: Weibull pembrolizumab scenario; c: generalised gamma pembrolizumab scenario; d: exponential pertuzumab 
scenario; e: Weibull pertuzumab scenario; f: generalised gamma pertuzumab scenario. 
